Author Archives: Natalie Themm
U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam for Pediatric Patients with Tourette Syndrome
Ecopipam (EBS-101) is a first-in-class selective D1 (dopamine) receptor antagonist with Orphan Drug designation
Sera Prognostics Appoints Scott Gleason CFO
SALT LAKE CITY, Aug. 19, 2026 /PRNewswire/ — Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, announced today that Scott Gleason has been appointed Chief Financial Officer (CFO), effective August 31, 2026. Mr. Gleason brings more than 25 […]
Merit Medical Announces Global Operations Leadership Transition
Sheri Lewis has agreed to join Merit as Executive VP of Global Operations, effective August 31.
Utah Life Sciences Innovation Caucus Breakfast
Utah lawmakers on Aug, 19 attended a breakfast meeting of the Utah Life Sciences Innovation Caucus (ULSIC).
Curavit Expands Clinical Research Capabilities with Acquisition of Lindus Health CRO Assets, Accelerating Global Trial Execution for Life Science Sponsors
Combined operations deliver unified trial delivery, faster recruitment, and expanded evidence-generation capabilities.
Sethera Therapeutics’ Polymacrocyclic Peptide Platform Selected for CDMRP-Supported Mutant p53 Breast Cancer Program
The award supports innovative, high-impact research aimed at advancing the prevention, diagnosis, and treatment of breast cancer.
Clene Announces Biomarker Analyses To Be Included in NDA Submission Supporting ALS Accelerated Approval
Survival benefit is concentrated in participants with NfL biomarker response.
CancerVax Achieves Major Milestone in Activating Human Killer T-Cells Against Cancer
In-vitro studies confirmed revolutionary therapy successfully disguised liver cancer cells as virally infected cells and activated pre-existing human antiviral Killer T-cells.
Teledyne to Acquire Varex Imaging Corporation
Teledyne will acquire all of the outstanding common shares of Varex for $18.90 per share, payable in cash.
Strategic Transactions Advocacy Track (STAT)
STAT delivers U.S. Government Advocacy for Foreign Investment & Concession Projects
London Stock Exchange: Biggest Changes to AIM Rules in Two Decades
For more than 30 years, AIM has been Europe’s most successful growth market.
Receptor.AI, Sethera Plan to Create Closed-Loop Discovery, Optimization Workflow for Difficult Therapeutic Targets
Receptor.AI and Sethera partner to create a closed-loop drug discovery workflow.
